PMID- 36969030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230328
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment 
      of metastatic breast cancer: two cases of premature interruption of therapy and 
      exceptional response.
PG  - 1067264
LID - 10.3389/fonc.2023.1067264 [doi]
LID - 1067264
AB  - Cancer treatment-related adverse events (AEs) are sometimes associated with 
      outcomes for cancer patients, especially with the newest therapies such as target 
      therapy and immunotherapy. A few years ago, the first-line therapy for 
      hormone-receptor-positive metastatic breast cancer (mBC) patients has been deeply 
      changed by the introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors, and 
      now, we are improving our knowledge about their AEs and significance in clinical 
      practice. Here, we report our experience with two cases of vitiligo-like lesions 
      that occur early during treatment with ribociclib. We tried to change the CDK4/6 
      inhibitor for one patient, but the skin reaction persisted. Both patients 
      retained only the endocrine therapy alone and had an unexpected durable 
      progression-free survival (PFS). Some data on skin toxicities, including 
      vitiligo-like lesions by CDK4/6 inhibitors, have recently been reported in the 
      literature, but for the first time, we highlight a possible correlation with 
      improved survival outcomes of patients. Uncovering the etiology of this toxicity, 
      verifying the involvement of the immune system, and demonstrating a possible 
      positive impact in survival represent an intriguing research objective for the 
      near future.
CI  - Copyright (c) 2023 Pasqualoni, Orlandi, Palazzo, Garufi, Cannizzaro, Pontolillo, 
      Pannunzio, Cutigni, Sollena, Federico, Bria and Tortora.
FAU - Pasqualoni, Mariangela
AU  - Pasqualoni M
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Orlandi, Armando
AU  - Orlandi A
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
FAU - Palazzo, Antonella
AU  - Palazzo A
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
FAU - Garufi, Giovanna
AU  - Garufi G
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Cannizzaro, Maria Chiara
AU  - Cannizzaro MC
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Pontolillo, Letizia
AU  - Pontolillo L
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Pannunzio, Sergio
AU  - Pannunzio S
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Cutigni, Claudia
AU  - Cutigni C
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Sollena, Pietro
AU  - Sollena P
AD  - Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 
      Rome, Italy.
FAU - Federico, Francesco
AU  - Federico F
AD  - Department of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 
      Rome, Italy.
FAU - Bria, Emilio
AU  - Bria E
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
FAU - Tortora, Giampaolo
AU  - Tortora G
AD  - Comprehensive Cancer Center, Medical Oncology Unit, Fondazione Policlinico 
      Universitario 'A. Gemelli' - IRCCS, Rome, Italy.
AD  - Catholic University of Sacred Heart, Rome, Italy.
LA  - eng
PT  - Case Reports
DEP - 20230309
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10034067
OTO - NOTNLM
OT  - CDK4/6 inhibitor
OT  - breast cancer
OT  - lymphocytic infiltration
OT  - skin adverse event
OT  - vitiligo
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/28 06:00
MHDA- 2023/03/28 06:01
PMCR- 2023/01/01
CRDT- 2023/03/27 03:32
PHST- 2022/10/11 00:00 [received]
PHST- 2023/02/17 00:00 [accepted]
PHST- 2023/03/27 03:32 [entrez]
PHST- 2023/03/28 06:00 [pubmed]
PHST- 2023/03/28 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1067264 [doi]
PST - epublish
SO  - Front Oncol. 2023 Mar 9;13:1067264. doi: 10.3389/fonc.2023.1067264. eCollection 
      2023.